Planning the hepatitis C virus elimination in Cyprus: A modeling study

Table 1 Model parameters and references

Parameter	Estimate	Ref.
Total chronic hepatitis C population size in the Republic of Cyprus	2900	[13]
Chronic hepatitis C population size in the Republic of Cyprus among the general population	2600	[13]
Chronic hepatitis C population size in the Republic of Cyprus among PWID	300	[16]
Proportion who are acutely infected and spontaneously clear infection	26%	[28]
PWID population	700	[16]
Duration of injecting carrier among PWID (yr)	13.5	[16]
Proportion of sharers	43%	[16]
Overall PWID mortality	2%	[29]
New diagnoses	30	[5]
Proportion participating in harm reduction programs (OST or high coverage HCNSP)	25%	[16]
Relative risk for HCV infection while in a harm reduction program	0.5	[14]
SVR IFN-free DAAs	95%	[17-19]
HCV Progression rates per yr
F0→F1	0.176	[30]
F1→F2	0.082	[30]
F2→F3	0.100	[30]
F3→F4	0.161	[30]
F4→Decompensated cirrhosis	0.04	[31,32]
F4→Hepatocellular carcinoma	0.021	[31,32]
Decompensated cirrhosis→Death related to HCV	0.306	[31,32]
Hepatocellular carcinoma→Death related to HCV	0.433	[31,32]
Decompensated cirrhosis→Hepatocellular carcinoma	0.021	[31,32]

DAAs: Direct-acting antivirals; HCNSP: High-coverage needle and syringe programs; HCV: Hepatitis C virus; IFN: Interferon; OST: Opioid substitution treatment; PWID: People who inject drugs; SVR: Sustained virologic response.